sn-Glycero-3-phosphocholine
(Synonyms: 甘磷酸胆碱; Choline Alfoscerate; Alpha-GPC; L-α-GPC) 目录号 : GC12123
A nootropic phospholipid
Cas No.:28319-77-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
Treatment with sn-Glycero-3-phosphocholine (Choline Alfoscerate) (250 mg/kg; i.m.; daily for 3 weeks) after seizure can improve seizure-induced cognitive impairment[2].sn-Glycero-3-phosphocholine (Choline Alfoscerate) increases the release of acetylcholine in rat hippocampus, facilitates learning and memory in experimental animals, improves brain transduction mechanisms and decreases age-dependent structural changes occurring in rat brain areas involved in learning and memory[3].
References:
[1]. Traini E, et al. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipidwith a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9.
[2]. Traini E, et al. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipidwith a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9.
[3]. Lee SH, et al. Late treatment with choline alfoscerate (l-alpha glycerylphosphorylcholine, α-GPC) increases hippocampal neurogenesis and provides protection against seizure-induced neuronal death and cognitive impairment. Brain Res. 2017 Jan 1;1654(Pt A):66-76.
| Cas No. | 28319-77-9 | SDF | |
| 别名 | 甘磷酸胆碱; Choline Alfoscerate; Alpha-GPC; L-α-GPC | ||
| 化学名 | [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate | ||
| Canonical SMILES | C[N+](C)(C)CCOP(=O)([O-])OCC(CO)O | ||
| 分子式 | C8H20NO6P | 分子量 | 257.22 |
| 溶解度 | ≥ 11.2mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8877 mL | 19.4386 mL | 38.8772 mL |
| 5 mM | 0.7775 mL | 3.8877 mL | 7.7754 mL |
| 10 mM | 0.3888 mL | 1.9439 mL | 3.8877 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。